[1]晏婉清 吴昕悦 任勇.慢性肾脏病与难治性高血压[J].心血管病学进展,2024,(12):1088.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.008]
　YAN Wanqing,WU Xinyue,REN Yong.Chronic Kidney Disease with Resistant Hypertension[J].Advances in Cardiovascular Diseases,2024,(12):1088.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.008]
点击复制

慢性肾脏病与难治性高血压()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2024年12期
页码:
1088
栏目:
综述
出版日期:
2024-12-25

文章信息/Info

Title:
Chronic Kidney Disease with Resistant Hypertension
作者:
晏婉清1; 2 吴昕悦1; 2 任勇2
(1. 武汉科技大学医学部医学院,湖北 武汉 430000 ;2. 湖北文理学院附属医院 襄阳市中心医院心血管内科 湖北文理学院心血管病研究所,湖北 襄阳 441000)
Author(s):
YAN Wanqing1; 2; WU Xinyue 1; 2; REN Yong 2
(1. School of Medicine,Wuhan University of Science and Technology,Wuhan 430000,Hubei,China; 2. Department of Cardiology,Institute of Cardiovascular Diseases,Xiangyang Central Hospital,Affiliated Hospital of Hubei University of Arts and Science,Xiangyang 441000,Hubei,China)
关键词:
难治性高血压; 慢性肾脏病; 利尿剂; 盐皮质激素受体拮抗剂
Keywords:
Resistant hypertension; Chronic kidney disease; Diuretic; Mineralocorticoid receptor antagonist
DOI:
10.16806/j.cnki.issn.1004-3934.2024.12.008
摘要:
难治性高血压是指同时使用3种抗高血压药，血压仍高于目标水平，或至少需要4种药物才能控制血压的严重高血压类别。在高血压患者中，其患病率为5%～15%，而在慢性肾脏病患者中，患病率是普通人群的2～3倍。但肾功能损害及高钾血症等原因限制了螺内酯等高效抗高血压药的使用、增加了治疗难度，慢性肾脏病一旦诊断难治性高血压，最重要的是根据主要病理生理机制针对性地个体给药。现将从慢性肾脏病中难治性高血压的流行病学、特有的病理生理机制、诊断及其治疗进展等方面进行论述。
Abstract:
Resistant hypertension is a category of severe hypertension in which blood pressure remains above target levels with the concurrent use of three antihypertensive medications,or in which at least four medications are required to control blood pressure. Among hypertensive patients,its prevalence is about 5%～15%,while in patients with chronic kidney disease,the prevalence of resistant hypertension is two to three times higher than that of the general population. Once diagnosed with re sistant hypertension ,patients with chronic kidney disease need to be treated individually according to the main pathophysiological mechanisms,but renal impairment and hyperkalemia limit the use of highly effective antihypertensive drugs such as spironolactone and increase the difficulty of treatment. Its therapeutic specificity needs to be learned together by clinicians. In this paper,we will review the epidemiology,specific pathophysiological mechanisms,diagnosis and therapeutic advances of resistant hypertension in chronic kidney disease.

参考文献/References:

[1] Wang Z,Chen Z,Zhang L,et al. Status of hypertension in China:results from the China hypertension survey,2012-2015[J]. Circulation,2018,137(22):2344-2356.

[2] 中国医疗保健国际交流促进会高血压病学分会,中国医疗保健国际交流促进会外周动脉病学分会,中国研究型医院学会高血压专业委员会,等. 难治性高血压血压管理中国专家共识[J/OL]. 中华高血压杂志,1-6[2024-11-07]. http://kns.cnki.net/kcms/detail/11.5540.R.20240603.1057.002.html.

[3] 中国高血压防治指南修订委员会,高血压联盟(中国),中国医疗保健国际交流促进会高血压病学分会,等. 中国高血压防治指南(2024年修订版)[J]. 中华高血压杂志(中英文),2024,32(7):603-700.

[4] Wu C,Wang Y,Zhang W,et al. Prevalence and characteristics of apparent treatment-resistant hypertension in older people in China:a cross-sectional study[J]. Clin Exp Hypertens,2019,41(8):753-758.

[5] Noubiap JJ,Nansseu JR,Nyaga UF,et al. Global prevalence of resistant hypertension:a meta-analysis of data from 3.2 million patients[J]. Heart,2019,105(2):98-105.

[6] Thomas G,Xie D,Chen HY,et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease:report from the chronic renal insufficiency cohort study[J]. Hypertension,2016,67(2):387-396.

[7] Musgrove J,Wolf M. Regulation and effects of FGF23 in chronic kidney disease[J]. Annu Rev Physiol,2020,82:365-390.

[8] Kawarazaki W,Mizuno R,Nishimoto M,et al. Salt causes aging-associated hypertension via vascular Wnt5a under klotho deficiency[J]. J Clin Invest,2020,130(8):4152-4166.

[9] Yao Y,Wang Y,Zhang Y,et al. Klotho ameliorates oxidized low density lipoprotein (ox-LDL)-induced oxidative stress via regulating LOX-1 and PI3K/Akt/eNOS pathways[J]. Lipids Health Dis,2017,16(1):77.

[10] Lanzer P,Boehm M,Sorribas V,et al. Medial vascular calcification revisited:review and perspectives[J]. Eur Heart J,2014,35(23):1515-1525.

[11] Simeoni M,Perna AF,Fuiano G. Secondary hyperparathyroidism and hypertension:an intriguing couple[J]. J Clin Med,2020,9(3):629.

[12] Zhang H,Chen J,Shen Z,et al. Indoxyl sulfate accelerates vascular smooth muscle cell calcification via microRNA-29b dependent regulation of Wnt/β-catenin signaling[J]. Toxicol Lett,2018,284:29-36.

[13] Vanholder R,Pletinck A,Schepers E,et al. Biochemical and clinical impact of organic uremic retention solutes:a comprehensive update[J]. Toxins (Basel),2018,10(1):33.

[14] Panizo S,Martínez-Arias L,Alonso-Montes C,et al. Fibrosis in chronic kidney disease:pathogenesis and consequences[J]. Int J Mol Sci,2021,22(1):408.

[15] Schiffrin EL,Pollock DM. Endothelin system in hypertension and chronic kidney disease[J]. Hypertension,2024,81(4):691-701.

[16] Mielke J,Trucks-Jansen H,Schurmann C,et al. Prevalence,phenotypic characteristics and prognostic role of apparent treatment resistant hypertension in the German Chronic Kidney Disease (GCKD) study[J]. J Hum Hypertens,2023,37(5):345-353.

[17] Bhatt H,Siddiqui M,Judd E,et al. Prevalence of pseudoresistant hypertension due to inaccurate blood pressure measurement[J]. J Am Soc Hypertens,2016,10(6):493-499.

[18] Clement DL,de Buyzere ML,de Bacquer DA,et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension[J]. New Engl J Med,2003,348(24):2407-2415.

[19] Mancia G,Kreutz R,Brunstr?m M,et al. 2023 ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European society of hypertension:endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA)[J]. J Hypertens,2023,41(12):1874-2071.

[20] Choudhry NK,Kronish IM,Vongpatanasin W,et al. Medication adherence and blood pressure control:a scientific statement from the American heart association[J]. Hypertension,2022,79(1):e1-e14.

[21] McMahon EJ,Campbell KL,Bauer JD,et al. Altered dietary salt intake for people with chronic kidney disease[J]. Cochrane Database Syst Rev,2021,6(6):CD010070.

[22] Chan S,Cameron A,Wang Z,et al. Body mass index in an Australian population with chronic kidney disease[J]. BMC Nephrol,2018,19(1):209.

[23] Carey RM,Moran AE,Whelton PK. Treatment of hypertension:a review[J]. JAMA,2022,328(18):1849-1861.

[24] Agarwal R,Sinha AD,Tu W. Chlorthalidone for resistant hypertension in advanced chronic kidney disease[J]. Circulation,2022,146(9):718-720.

[25] Williams B,MacDonald TM,Morant S,et al. Spironolactone versus placebo,bisoprolol,and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2):a randomised,double-blind,crossover trial[J]. Lancet,2015,386(10008):2059-2068.

[26] Agarwal R,Rossignol P,Romero A,et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER):a phase 2,randomised,double-blind,placebo-controlled trial[J]. Lancet,2019,394(10208):1540-1550.

[27] Agarwal R,Pitt B,Palmer BF,et al. A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease[J]. Clin Kidney J,2022,16(2):293-302.

[28] Williams B,MacDonald TM,Morant SV,et al. Endocrine and haemodynamic changes in resistant hypertension,and blood pressure responses to spironolactone or amiloride:the PATHWAY-2 mechanisms substudies[J]. Lancet Diabetes Endocrinol,2018,6(6):464-475.

[29] Bakris GL,Agarwal R,Anker SD,et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes[J]. N Engl J Med,2020,383(23):2219-2229.

相似文献/References:

[1]周小琳 何泉.替格瑞洛在急性冠脉综合征合并慢性肾脏病患者中的应用研究进展[J].心血管病学进展,2019,(5):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
　ZHOU Xiaolin,HE Quan.Ticagrelor in Acute Coronary Syndrome with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2019,(12):718.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.014]
[2]黄毕.慢性肾脏病合并动脉粥样硬化性心血管疾病的调脂治疗进展[J].心血管病学进展,2020,(10):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
　HUANG Bi.Lipid Management in Patients with Chronic Kidney Disease and Arteriosclerotic Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2020,(12):1065.[doi:10.16806/j.cnki.issn.1004-3934.2020.10.016]
[3]陈纪元 陆泓雨 贺子熠 韩江莉.冠心病合并慢性肾脏病患者P2Y12受体拮抗剂治疗进展[J].心血管病学进展,2022,(7):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
　CHEN Jiyuan,LU Hongyu,HE Ziyi,et al.P2Y12 Antagonists for Patients with Chronic Kidney Diseases and Coronary Heart Diseases[J].Advances in Cardiovascular Diseases,2022,(12):582.[doi:10.16806/j.cnki.issn.1004-3934.2022.07.000]
[4]魏志梁 孙雨可 尹月娇 孙守刚.心房颤动合并慢性肾脏病患者的左心耳封堵治疗研究进展[J].心血管病学进展,2022,(9):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
　WEI Zhiliang,SUN Yuke,YIN Yuejiao,et al.Left Atrial Appendage Closure in Patients with Atrial Fibrillation Complicated with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2022,(12):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
[5]陈道乾 何胜虎.重度主动脉瓣狭窄合并慢性肾脏病患者经导管主动脉瓣置换术研究进展[J].心血管病学进展,2024,(8):686.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.004]
　CHEN Daoqian,HE Shenghu.Transcatheter Aortic Valve Replacement in Patients with Severe Aortic Stenosis Combined with Chronic Kidney Disease:a Study in Progress[J].Advances in Cardiovascular Diseases,2024,(12):686.[doi:10.16806/j.cnki.issn.1004-3934.2024.08.004]
[6]姚媛媛 张鑫 叶润宇 陈晓平.难治性高血压的认识和治疗进展[J].心血管病学进展,2024,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.007]
　YAO Yuanyuan,ZHANG Xin,YE Runyu,et al.Recognition and Treatment of Resistant Hypertension[J].Advances in Cardiovascular Diseases,2024,(12):1084.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.007]
[7]刘志斌,唐毅,胡政琪,等.人附睾蛋白4在心肾疾病中的研究进展[J].心血管病学进展,2024,(12):1110.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.012]
　LIU ZhibinTANG YiHU ZhengqiLIU TianchengPENG JianqiangHE Jin*.Human Epididymal Protein 4 in Cardiovascular and R enal Diseases[J].Advances in Cardiovascular Diseases,2024,(12):1110.[doi:10.16806/j.cnki.issn.1004-3934.2024.12.012]

更新日期/Last Update: 2025-01-08